Thermo Fisher Q1 Revenue Hits $11.01B, EPS Beats Estimates, Flags Inflation Risk
Thermo Fisher reported Q1 adjusted EPS of $5.44 beating consensus by $0.20, while GAAP EPS of $4.43 missed estimates, and revenue reached $11.01 billion versus $10.86 billion forecasts. The company cautioned that Middle East tensions present a modest inflation risk to supply chains and highlighted a debt-to-equity ratio of 0.83.
1. Q1 Financial Results
Thermo Fisher reported Q1 adjusted earnings of $5.44 per share, surpassing the consensus by $0.20, while GAAP diluted EPS came in at $4.43, below the $5.20 estimate. Revenue rose to $11.01 billion, topping forecasts by $0.15 billion, driven primarily by strength in laboratory products and biopharma services.
2. Inflation Risk Warning
Management cautioned that escalating tensions in the Middle East pose a modest inflation risk, potentially increasing raw material and logistics costs across its global supply chain. The company is deploying cost control measures and adjusting procurement strategies to mitigate upward price pressures.
3. Balance Sheet Strength
Thermo Fisher maintained a debt-to-equity ratio of 0.83 and a current ratio of 1.53, underscoring its ability to manage liabilities and short-term obligations. Strong cash reserves and disciplined capital allocation support ongoing R&D investments and strategic acquisitions.